184 related articles for article (PubMed ID: 35059998)
21. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
22.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
23. Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies.
Bodar Y; Koene B; Meijer D; van Leeuwen PJ; Nadorp S; Donswijk ML; Hendrikse NH; Oprea-Lager DE; Vis AN
Urol Oncol; 2022 Feb; 40(2):58.e1-58.e7. PubMed ID: 34404590
[TBL] [Abstract][Full Text] [Related]
24.
Wang R; Shen G; Yang R; Ma X; Tian R
Eur J Radiol; 2020 Sep; 130():109131. PubMed ID: 32622250
[TBL] [Abstract][Full Text] [Related]
25. Comparison of
Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
[TBL] [Abstract][Full Text] [Related]
26. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
27. Intraindividual comparison between
Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
[TBL] [Abstract][Full Text] [Related]
28. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Ravi Kumar AS; Lawrentschuk N; Hofman MS
Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
31. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
32. Intraindividual Comparison of
Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
[No Abstract] [Full Text] [Related]
33. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
34. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
36. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
37. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
38. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.
Young S; Liu W; Zukotynski K; Bauman G
Expert Rev Anticancer Ther; 2021 Jun; 21(6):641-655. PubMed ID: 33476253
[TBL] [Abstract][Full Text] [Related]
40. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]